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Abstract
We describe the case of a patient implanted with a DeBakey left ventricular assist device (LVAD) as bridge to transplant who survived 7 h
of ventricular fibrillation. He was successfully converted into a stable sinus rhythm.
q 2004 Elsevier B.V. All rights reserved.
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1. Background
Ventricular fibrillation (VF) is a pulseless arrhythmia in
which chaotic electrical activity causes absence of ven-
tricular contraction with immediate loss of cardiac output.
The subsequent hypo-perfusion creates global tissue
ischaemia; brain and myocardium are most susceptible
organs and it may lead to irreparable damage and death if
not treated immediately [1]. VF is the primary cause of
sudden cardiac death in the world. Regular cardiac activity
can be restored with mechanical resuscitation or external
DC defibrillation. The most important determinant of
survival in VF is rapid defibrillation [2]. American Heart
Association Guidelines 2000 conference recommends that
early defibrillation be available throughout all hospital and
outpatient medical facilities [3].
With the rising incidence of congestive heart failure
(CHF) due to the aging population, mechanical circulatory
support pose themselves as interesting adjuvant therapeutic
option. According to the REMATCH study [4], the use of
left ventricular assist devices (LVAD) resulted in over twice
the survival rate and an improved quality of life, in
comparison to optimal medical management. Since 1988
researchers from the Baylor College of Medicine (Houston,
TX) with engineers from NASA have developed the
DeBakey LVAD (MicroMed Inc.) [5]. This implantable
continuous flow blood pump creates a maximal flow of
.10 l/min, providing relief to the sick heart by taking over
part of the pumping action [5]. As this LVAD has been
available in our centre since October 1999, we have
evaluated this new device in 17 patients.
We report the experience of one patient with a
continuous flow LVAD surviving sustained and documen-
ted VF for nearly 7 h.
2. Case report
A 61-year-old male suffering from a terminal heart
failure (NYHA class III–IV) and a left ventricular ejection
fraction of ,25% with two previous cardiac surgeries,
namely mechanical aortic valve replacement in 1987 and
implantation of a biventricular pacemaker in late 2001 is
presented. For a few months cardiac function has been
getting worse, and the patient felt a significant decrease of
quality of life. As ultimate treatment this patient was
selected for heart transplantation (HTX).
Based on our experience with mechanical support
systems, and the actual trend in the treatment of chronic
heart failure, an LVAD was indicated; this patient was
enrolled in our bridge to heart transplantation study and
received an LVAD [5,6] as bridge to heart transplantation.
This LVAD is a fully implantable miniaturised blood
pump used in patients suffering from terminal heart failure
[7]. It creates a constant flow (may exceed 10 l/min) and
provides supportive pump action for the sick heart.
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In the course of a multicentre study, we have successfully
implanted 17 patients. Eight have been successfully bridged
to HTX, 8 deaths occurred, 6 among 8 emergent implants and
2 among 7 elective procedures. As mortality of transplan-
tation candidates on waiting lists is high and with the
increased survival after HTX, LVAD are considered a safe
and efficient bridging tool in the setting of terminal heart
failure [4].
The patient was implanted successfully, successfully
weaned from the respirator on the second post-operative day
and transferred to the regular ward after 4 days. The rest of
his stay in the hospital was uneventful. He was released into
a specialised cardiac rehabilitation facility after 4 weeks.
Patients on LVAD support are discharged as soon as
possible into a cardiac rehabilitation centre. They come to
our centre once a week for a thorough check-up by our HTX
team. In this case all visits were satisfactory. Pulmonary
vascular resistance (PVR) decreases; increased exercise and
regression of plasma b-type natriuretic peptide (BNP) were
all stigmata of regressing heart failure. The patient himself
described his physical state as a rebirth and was good
spirited toward his upcoming HTX. The anticoagulation
regimen of all our LVAD patients consists of only
acetylsalicylic acid 100 mg/day and warfarin with an aim
INR of 1.5–2.5.
Eighteen days after discharge (73 days of LVAD
support), we received a call from the rehabilitation centre,
informing us that the patient was taken ill while on a long
walk during a hot summer day in the mountains. He had
suffered a sudden onset of light-headedness, nausea and cold
sweats, no collapse or loss of consciousness was noted.
After a short rest on a bench and a cold beverage, the
symptoms improved and he was bought back to the centre.
An ECG was immediately done showing what initially was
interpreted as atrial flutter activity with irregular pacemaker
activity. Immediate treatment was initiated (intravenous
saline and bolus of 300 mg Amiodarone) while the transfer
to our centre was organised.
On arrival at our hospital this oligosymptomatic patient
was walking about the hospital ward as if nothing happened.
Physical examination showed turgescent jugular veins and
absence of heart sounds, the pump making its normal
turbine like noise. Precordial ECG, however, showed VF
with irregular pacemaker activity. The patient was rapidly
transferred to the ICU. Pacemaker memory function
(MedTronic InSync III, with automatic diagnosis system)
yielded very surprising information, the onset of VF
happened 6 h prior the onset of symptoms. Pressure curves
displayed on the clinical data acquiring system (CDAS) of
the LVAD and on the ICU monitoring screens were
completely flat, attesting to the absence of left ventricular
ejection (Fig. 1). Absence of flow through the aortic valve
and impactment of the right ventricle on the left were
documented by echography (Fig. 2). The INR was 2.7 and
potassium was found at 4 mmol/l. Heart enzymes had risen
significantly (Troponin T 5.88 mg/l, CK tot. 712 U/l,
CK-Mb act. 71 U/l, Myoglobin 278 mg/l). After intravenous
sedation (propofol and fentanyl) and bolus of 5000 IE heparin
we proceeded to electroconvert the patient. Three attempts
with A/P external defibrillation (360 J) and intravenous
lidocaine were necessary to restore regular sequential paced
heart rhythm. Restored left ventricular ejection and flow
through the aortic valve were observed on echocardiography,
cardiovascular monitoring and on the display of the CDAS.
The patient regained consciousness a few minutes later with a
stable cardiac rhythm requiring no pharmacological support.
Laboratory values showed a normalisation of
cardiac enzymes after 5 days (Troponin T 1.61 mg/l, CK
tot. 73 U/l, CK-Mb act. 11 U/l, Myoglobin 88 mg/l).
Twelve hours after defibrillation the patient developed
severe neurological symptoms. A cerebral CT-scan showed
a massive frontal intra-cerebral haemorrhage. Upon this all
anticoagulation was stopped. The patient never recuperated
from this neurological event and the LVAD was turned of
14 of ICU treatment.
3. Comment
Very few reports describing survival after sustained VF
exist in the literature, VF being lethal if not treated
immediately [8,9].
Fig. 1. ICU monitoring before electro conversion.
Fig. 2. Trans thoracic echocardiography (during VF) shows accelerated
flow through compressed left ventricle with dilated right ventricle.
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This LVAD provides assistance for the failing heart. In
this report we illustrate the role of this small device creating
sufficient blood flow to allow viable end-organ function
even with absence of left ventricular ejection.
The mechanisms causing VF are well known. Generally
the aetiology is cardiac (dilatative or ischaemic cardiomyo-
pathy) or metabolic. We believe that hypo-kaliemia induced
through the diuretic action of furosemide combined with an
excess of physical exercise under extreme conditions
(altitude, heat, sun) caused this arrhythmia. The patient
having an underlying cardiomyophathy known to cause
arrhythmia, this VF was probably precipitated by the
hypokaliemia.
By survival and recuperation of efficient cardiac activity
after such a long period of VF, the normalisation of cardiac
enzymes (CK, Myoglobin, Troponin T) provide insight
into the physiological consequences of VF. The flow
(2.5–3.4 l/min) provided by the LVAD, was sufficient to
avoid irreversible ischaemic cardiac damage. In contrast to
the maximum flow capacity of this device (.10 l/min) the
turbine was functioning in a low speed mode (only
8500 rpm—maximum 15,000 rpm). This shows the inten-
sity of necessary flow to effectively replace cardiac output.
The physiological mechanism allowing a sustained
effective pulmonary circulation in the absence of left
ventricular ejection is due to two factors: the increase in
central venous pressure and the negative pressure at the
inflow-tract generated by the turbine in this micro-axial
pump. The blood is passively moved through the lungs,
suctioned by the turbine and propelled into the aorta. In this
case this was enough to allow sufficient oxygenation and
end organ perfusion for survival.
This report demonstrates the efficacy of the LVAD not
only as circulatory support but also as effective substitute in
absence of any cardiac activity.
Bleeding is the most frequent complication of mechan-
ical support systems (MCS). But the medical management
of terminal heart failure very often includes oral antic-
oagulation and platelet inhibition of any kind. In this case,
retrospectively one could consider that the IV bolus of
heparin (standard protocol for electro conversion) may have
lead to the neurological outcome. We also believe that it is
further necessary to study the precise effects of heparin,
continuous flow and the brain blood barrier, all this in
the setting of long-term support periods which destination
therapy patients will undergo.
Furthermore the question now may arise as to the
artificial heart. If left ventricular assistance is sufficient for
life support, additional fully implantable devices replacing
the heart will not be necessary, adding implantable
automatic defibrillators would be enough for long-term
assistance. Further studies are being conducted in this field,
and we hope that our experience will be a valuable brick in
the fight against heart failure.
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